Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON trial of bevacizumab added to temozolomide-based chemotherapy for relapsed or refractory neuroblastoma
NL-OMON58933Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab, temozolomide, irinotecan and topotecan in neuroblastoma (2 arms), sponsored by University of Birmingham. Primary endpoints: Best response and Progression-free survival. Started Jul 2015; status: completed.
02
Drugs
bevacizumabtemozolomideirinotecantopotecan
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NL-OMON58933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58933.